Last reviewed · How we verify

NCT06944925

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting now Phase 1 Last updated 14 May 2025
What this trial tests

Phase 1 trial testing BBT002 in Chronic Obstructive Pulmonary Disease in 98 participants. Currently enrolling.

Timeline
8 May 2025
Primary endpoint
31 October 2026
31 March 2027

Quick facts

Lead sponsorBambusa Therapeutics
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingtriple
Primary purposetreatment
Enrollment98
Start date8 May 2025
Primary completion31 October 2026
Estimated completion31 March 2027
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Bambusa Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, blinded, placebo-controlled single (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of BBT002 in healthy volunteers (HVs) and in adult patients with Chronic Obstructive Pulmonary Disease (COPD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of BBT002

Trials testing the same drug.

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Bambusa Therapeutics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06944925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing